Dissertation > Excellent graduate degree dissertation topics show

The Observation of the Therapeutic Effect of Intermediate-dose Cytarabine for Acute Leukemia

Author: LiHuiYing
Tutor: YaoCheng
School: Jilin University
Course: Clinical
Keywords: acute leukemia intermediate-dose cytarabine post-remission refractory and relapse
CLC: R733.7
Type: Master's thesis
Year: 2005
Downloads: 61
Quote: 0
Read: Download Dissertation

Abstract


Acute leukemia is a malignancy with the clonal expansion of immature cell.Theincidence rate of adult acute leukemia is 2.76 per 100 thousands.In adult acutemyeloid leukemia complete remission(CR) rates of 60%-70% can be achieved andin adult acute lymphoblastic leukemia is 70-85%.The therapy of AL is including: combination chemotherapy, stem celltranspantation, targeted therapy.Chemotherapy is the most importance of all andchemotherapy is made of remission-induction aand intensive consolidation orpost-remission therapy.In recent years,although chemotherapy can achieve a high rate of diseaseremission induction in patients with AL,patients with recurrent or refractoryAL generally have a poorer rate of response.and more than 50% of them thenrelapse.Part of patients with relapsed or refractory AL who received high-dosecytarabine can achieve CR, and the patients with post-remission can prolong CRtime .The theory is the concentration of cytarabine in plasma would be enhancedby increasing drug`s dose and the therapeutic ara-c levels persisted in thecentral nervous system.So I(H)D-Ara-C provided a sufficient plasma ara-c levelwith a concomitant therapeutic concentration in the cerebrospinal fluid and theycan kill more leukemia wells while the toxicity is tolerable.In an attempt to increase the proportion of patients with ALremaining inlong-term disease-free survival and raise the remission rate of patients withrecurrent or refractory AL. We use intermediate-dose (0.5-1.0g/㎡) cytarabinesingle or combinate other drugs to 80 patients who seeked medical services inour hospital from 1994 to 2005. Results as follows:To post-remission therapy: InAMLpatients,themedianCR durationof theID-Ara-Cgroupandthecontrolgroup who did not receive ID-Ara-C therapy was 9 months(4-24) and 6.5 months(3-19),respectively.There is significant difference between them . In ALLpatients , the median CR duration of the ID-Ara-C group and the control groupwho did not receive ID-Ara-C therapy was 8.5months(4-31) and 4 months(2-19),respectively.There is significant difference between them . The resultshows the ID-Ara-C can prolong the CR duration. In AML patients,the actuarial 1and 2 years DFS was 45% and 8% for ID-Ara-Cgroup versus 20% and less than 1% for the control group.There was significantdifference between them fou one year,but no difference for two years.The resultsare different with other reports.Analysis of the results, we considered oursample was too small and follow-up time was too short,the most important reasonis most of our patients receive ID-Ara-C therapy only for one course,the drug`seffect is not significant . In ALL patients , the actuarial 1yearsDFS was 54.5% for ID-Ara-C groupversus 21.4% for the control group.There was significant difference between

Related Dissertations

  1. The Expression and Correlation Analysis of MT1A and MT1X in Patients with Acute Leukemia,R733.71
  2. Children with acute leukemia also prototype folate carrier gene polymorphism,R733.71
  3. Effects of Informational and Emotional Surpport on Family Function and Quality of Life in Family Members with Acute Leukemia Children,R733.7
  4. The Value of Routine Bone Marrow Examination for the Diagnosis of Idiopathic Thrombocytopenic Purpura in Adults,R554.6
  5. The Expression and Significance of Angiogenin-2 and VEGF in Acute Leukemia,R733.7
  6. A Study of Family Function and Quality of Life of Acute Leukemia Children’ Parents in Hunan Province,R473.73
  7. Clinical Significance of Detection in the Serum and CSF Levels of SDF-1 in Patients with Acute Leukemia,R733.7
  8. Expression and Clinical Significance of CDX2 in Acute Leukemia,R733.7
  9. The Expression and Significance of HIF-1α in Patients with Acute Leukemia and Its Relationship with IGF-I,R733.71
  10. Affection of Ara-C in Expression of cFLIP_L mRNA in Primary Acute Leukemic Cells,R733.7
  11. The Expression and Significance of NR4A1 in Patients with Acute Leukemia and Its Relationship with Caspase-3,R733.71
  12. The Clinical Analysis of Characteristic and Therapy of Acute Graft-versus-host Disease after Related Allogenic Hematopoietic Stem Cell Transplantation,R392
  13. Expression and Significance of Integrin Linked Kinase and Protein Kinase B in Acute Leukemia,R733.7
  14. Expression and Clinical Significance of CD74 and P65 in Acute Leukemia,R733.71
  15. Co-localization of NS and PPP2R5A in HL-60 Leukemia Cells and the Construction of pCMV Myc-PPP2R5A Expression Vector,R733.71
  16. Expression and Clinical Significance of TAp63 and Bcl-2 in Acute Leukemia,R733.7
  17. The Research of ALK (Anaplastic Lymphoma Kinase, ALK) Gene and NPM-ALK (Nucleophosmin-anaplastic Lymphoma Kinase, NPM-ALK) Fusion Gene in Children with Acute Leukemia,R733.7
  18. Studies on the Mechanisms of the Reciprocal Regulation between Regulator of Calcineurin 1 and NF-κB and the Inhibition of Acute Leukemia Cells Viability,R733.7
  19. Expression of MicroRNA-486 in Patients with Acute Leukemia,R733.71
  20. A Preliminary Study on the Implication of Apaf-1 Promoter Methylation and the Expression of Apoptosis Inhibitor Protein Apollon in Adult Acute Leukemia,R733.71
  21. Expression of RYBP、 BMI1 and LSD1 Protein in Acute Leukemia,R733.71

CLC: > Medicine, health > Oncology > Hematopoietic and lymphoid neoplasms > Leukemia
© 2012 www.DissertationTopic.Net  Mobile